"The meeting we held in December was the first time I witnessed a change from people being predominantly exercised about their own sensitivities to being prepared to find middle ground," he says. "A lot of decisions at the last two meetings were made in areas we previously hadn't been able to touch." Increasing the pace is the imminent US election season. If there isn't an agreement within the next few months before it starts, political positioning will prevent the US sealing a deal until 2017 when the new president is in place. Mind boggling in its complexity (the US takes 80 specialists to each negotiation, Japan 120, and Australia 22) the negotiating text is secret. Robb says even most of the negotiators don't know what's in the whole thing. Each knows about little more than the chapter they are working on and there are more than 20 chapters. The text won't be made public until after the leaders shake hands, as is typical in international trade agreements. But what is known, from draft chapters leaked to Wikileaks and from the generally more open US political system, suggests that it's about far more than trade. Health

When the US negotiated its 2004 free trade agreement with Australia it pushed to eliminate "price controls", by which it meant the prices set by Australia's Pharmaceutical Benefits Scheme. What it got was an independent review process which had no authority to overturn decisions. Public health expert Dr Deborah Gleeson of La Trobe University says it's only been used twice. For the TPP the US wants something much stronger, the right to appeal against decisions and have them overturned. It would apply to decisions about both the prices charged for drugs and which drugs to include in the scheme (and in similar schemes in other countries). Among Australia's most expensive medicines are so-called biologics - drugs or vaccines made from living organisms. They are used to treat conditions including breast cancer and multiple sclerosis. To get approved in Australia the manufacturer needs to submit data from clinical trials which remains confidential for 5 years, and is then available to competitors to use in seeking approval for much cheaper versions. The US wants signatories to the TPP to lift the period of exclusivity to 12 years, which is what it is in the US. It would mean up to 7 more years of very expensive biologic medicines in Australia before the prices drop. Gleeson and colleagues reckon the extension would cost Australia more than $205 million a year. Most of the money would go to US owned pharmaceutical companies. A relatively rich country such as Australia can afford to send more money to the US for its medicines. Poorer nations such as Malaysia, Peru and Vietnam would find it harder. Robb responds by saying the critics don't know what will be in the final agreement. "They might know what the US position is but there are 11 other countries, right? A lot of us are waiting to see what the rest of the package looks like. We're not going to give up on something unless we get something somewhere else."

It's that flexibility, the fear that health protection measures could be traded away to get something else that worries organisations such as the Australian Medical Association. It says the US wants "industry" to have a guaranteed right to contribute to national nutrition policy making in member countries. It would mean letting the food industry help draft anti-obesity campaigns. If the tobacco industry had been given the right to help draft anti tobacco campaigns they would have taken place later and been less effective. Sovereignty Australia is currently being sued in an international tribunal by Philip Morris Asia after the tobacco giant lost its case in the High Court against Australia's plain packaging law. It is only able to do that because of an investment treaty Australia signed with Hong Kong. Philip Morris moved its Australian business to Hong kong to take advantage of it.

So-called investor-state dispute settlement procedures are common in international treaties. The US has insisted on them in all its free trade agreements but one. Australia is the exception. The Howard government said no in 2004 arguing that Australia's legal system was good enough to resolve any disputes it would have with the US without the need for an outside one. This time the US wants a universal system. The previous Labor government refused to have them in any of its trade agreements and believed it was on the verge of getting a carve out for Australia in the TPP because of its strong judicial system. But shortly after taking over the new trade minister, Andrew Robb said he would instead consider agreeing to them on a case by case basis, depending on what he got in return. The statement weakened Australia's ability to get a carve out. High Court Judge Robert French has complained that the judiciary is being frozen out of the decision making process. It knows more than any other branch of government about what allowing outside appeals beyond the High Court would do to the legal system, but he says as far as he knows, he hasn't been asked. Intellectual property The US is demanding extreme extensions in copyright terms. Already in the US-Australia Free Trade Agreement it secured an extension from 50 years after the author's death to 70, something former productivity Commission economist Philippa Dee believes cost Australia $88 million in extra copyright payments. Now it wants to make 70 years universal in those countries that don't have it and to extend the copyright on movies and sound recording from 70 years after publication to 95 years. And it wants to turn into criminal offences breaches of copyright that presently attract only civil penalties.

Robb says none of this is known, in part because the decisions haven't yet been taken, but leaks from inside the negotiations suggest that most of the intellectual property chapter has been finalised. What's in it for us? An Australian National University study of the US-Australia Free Trade Agreement found there was very little in it for Australia. A recent US department of agriculture study found it would deliver a zero economic benefit to Australia and a zero economic benefit to the United States. For smaller nations the economic benefits are bigger which may explain why they are eager to join and why the US is driving a hard bargain on intellectual property and the rights of its pharmaceutical industry. Robb is more optimistic. He says we'll like the agreement when we see it. It'll have to go to parliament. Until then he says we'll have to trust him. Peter Martin is economics editor of The Age.